Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?

Eli Lilly and Company’s (LLY) shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed first-quarter estimates for earnings but beat the same for sales. Sales of key drugs, Mounjaro, Zepbound, Jardiance, and Taltz beat estimates, while only Verzenio missed expectations. Lilly’s new products also contributed to sales growth. Trulicity sales continued to decline in the quarter.Lilly maintained its sales guidance for 2025 while lowering its earnings expectations to account ...